Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.

GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far

Pedrosa, Maurício Reis, Franco, Denise Reis, Gieremek, Hannah Waisberg, Vidal, Camila Maia, Bronzeri, Fernanda, de Cassia Rocha, Alexia, de Carvalho Cara, Luis Gabriel, Fogo, Sofia Lenzi, Eliaschewitz, Freddy Goldberg · 2022 · Current Atherosclerosis Reports

Abstract

Purpose of review To discuss evidence supporting the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective drug. Obesity is not just a hypertrophy of the adipose tissue because it may become dysfunctional and inflamed resulting in increased insulin resistance. Being overweight is associated with increased incidence of cardiovascular events and weight loss achieved through lifestyle changes lowers risk factors, but has no clear effect on cardiovascular outcomes. In contrast, treating obesity with GLP-1RA decreases cardiovascular risk and the possible mechanisms of cardioprotection achieved by this class of drugs are discussed. GLP-1RA were initially developed to treat type 2 diabetes patients, in whom the effects upon glycemia and, moreover, weight loss, especially with long-acting GLP-1RA, were evident. However, cardiovascular safety trials in type 2 diabetes patients, the majority presenting cardiovascular disease and excess weight, showed that GLP-1 receptor agonists were indeed capable of decreasing cardiovascular risk. Recent findings Type 2 diabetes treatment with GLP-1RA liraglutide and semaglutide paved way to a ground-breaking therapy specific for obesity, as shown with the SCALE 3 mg/day liraglutide program and the STEP 2.4 mg/week semaglutide program. A novel molecule with superior performance is tirzepatide, a GLP-1 and GIP (Gastric Inhibitory Peptide) receptor agonist and recent results from the SURPASS an…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11883-022-01062-2

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 121 references

Cited by

See all 76

Metadata

Authors
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G.
Corresponding author
Pedrosa, Maurício Reis
Venue
Current Atherosclerosis Reports
Published
2022-08-31
Volume
24
Issue
11
Pages
867-884
ISSN
  • 1523-3804 (ISSN-L)
  • 1534-6242
OpenAlex
W4293740201
Cited by
68
References
121
Citations by year
2026: 8 · 2025: 16 · 2024: 26 · 2023: 17 · 2022: 1
FWCI
2.16
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Current Atherosclerosis Reports (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
GLP-1 receptor agonists, obesity, cardiovascular disease prevention, cardioprotection, liraglutide, semaglutide, tirzepatide, type 2 diabetes, weight loss, insulin resistance, cardiovascular outcome trials, LEADER trial
MeSH terms
Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far. https://app.cochat.ai/papers/10.1007/s11883-022-01062-2
The paper
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022). GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-022-01062-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.